The further discussions imply that novel strategies of specifically targeting GB1 or GB2 or downstream signaling pathways of GABABRs may be effective in treating psychiatric disorders and equally efficacious in attenuating BE and BE‐related metabolism disorders. This evidence concerns the gene GABBR2 and metabolic disease.